Ultragenyx Pharmaceutical traded at $60.57 this Friday June 24th, increasing $0.58 or 0.97 percent since the previous trading session. Looking back, over the last four weeks, Ultragenyx Pharmaceutical gained 31.90 percent. Over the last 12 months, its price fell by 35.45 percent. Looking ahead, we forecast Ultragenyx Pharmaceutical to be priced at 58.94 by the end of this quarter and at 54.31 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
60.57
Daily Change
0.97%
Yearly
-35.45%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Kyowa Hakko Kirin 3,090.00 65.00 2.15% -20.87%
Acadia Pharmaceuticals 14.98 0.26 1.77% -42.76%
Agios Pharmaceuticals 22.57 1.29 6.06% -60.21%
Alnylam Pharmaceuticals 147.50 1.20 0.82% -15.90%
Aptinyx Inc 0.45 0.02 5.47% -84.70%
BioCryst Pharmaceuticals 10.76 0.59 5.80% -37.19%
Bluebird Bio 4.40 0.12 2.80% -85.77%
BioMarin Pharmaceutical 86.85 2.30 2.72% 2.43%
Epizyme 0.95 -0.003 -0.31% -90.18%
Esperion Therapeutics 6.47 0.18 2.86% -72.68%
Insmed 21.42 1.57 7.91% -25.98%
Ionis Pharmaceuticals 39.25 0.23 0.59% 0.82%
Karyopharm Therapeutics 5.17 0.04 0.78% -52.96%
MacroGenics 3.34 0.01 0.30% -87.71%
Moderna Inc 144.27 1.01 0.71% -34.40%
Mirati Therapeutics 68.16 2.27 3.45% -58.51%
Neurocrine Biosciences 98.24 0.84 0.86% -2.04%
Puma Biotechnology 2.85 -0.05 -1.72% -70.41%
PTC Therapeutics 40.22 0.11 0.27% -8.30%
Ultragenyx Pharmaceutical 60.57 0.58 0.97% -35.45%
Regeneron Pharmaceuticals 612.49 5.10 0.84% 11.25%
Sarepta Therapeutics 75.22 3.40 4.73% -6.44%
Vertex Pharmaceuticals 292.55 9.05 3.19% 50.54%
Immunic Inc. 3.80 -0.11 -2.81% -70.57%
Xoma 20.80 0.96 4.84% -41.36%

Indexes Price Day Year
USND 11608 375.43 3.34% -19.17%
US2000 1766 54.06 3.16% -24.36%

Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company's therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy and nucleic acid product candidates. Its three approved product candidates include Crysvita (burosumab), for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa), for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome and Dojolvi (triheptanoin), for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD). Its clinical product candidates include DTX401, for the treatment of glycogen storage disease type Ia (GSDIa), DTX301, for the treatment of ornithine transcarbamylase (OTC), UX143, GTX-102, UX701 and UX053.